Vorinostat

Nature Reviews Drug Discovery

Volumn 6, Issue 1, 2007, Pages 21-22

  Grant, Steven ^a   Easley, Chris ^b   Kirkpatrick, Peter ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOTOXIC AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CHROMATIN STRUCTURE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; NOTE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; DRUG APPROVAL; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33845897616     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2227     Document Type: Note

References (13)

1. Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: Past, present and future. Nature Rev. Drug Discov. 5, 37-50 (2006).
2. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769-784 (2006).
3. Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705-5708 (1996)
4. Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003-3007 (1998).
5. Yoshida, M. et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
6. FDA labelling information [online], (2006).
7. Kelly, W. K. & Marks, P. A. Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clin. Pract. Oncol. 2, 150-157 (2005).
8. Richon, V. M. et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014-10019 (2000).
9. Duvic, M. et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic Acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 7 Sep 2006 (doi: Blood-2006-06-025999v1).
10. Kim, E. J. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115, 798-812 (2005).
11. Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734 (2005).
12. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006).
13. Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673-678 (2005).